Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Operating Expenses: 2009-2024

Historic Operating Expenses for Iovance Biotherapeutics (IOVA) over the last 13 years, with Dec 2024 value amounting to $559.3 million.

  • Iovance Biotherapeutics' Operating Expenses rose 9.98% to $162.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $666.9 million, marking a year-over-year increase of 28.05%. This contributed to the annual value of $559.3 million for FY2024, which is 21.14% up from last year.
  • As of FY2024, Iovance Biotherapeutics' Operating Expenses stood at $559.3 million, which was up 21.14% from $461.7 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Operating Expenses registered a high of $559.3 million during FY2024, and its lowest value of $342.7 million during FY2021.
  • In the last 3 years, Iovance Biotherapeutics' Operating Expenses had a median value of $461.7 million in 2023 and averaged $473.3 million.
  • Data for Iovance Biotherapeutics' Operating Expenses shows a peak YoY rose of 21.14% (in 2024) over the last 5 years.
  • Over the past 4 years, Iovance Biotherapeutics' Operating Expenses (Yearly) stood at $342.7 million in 2021, then increased by 16.39% to $398.9 million in 2022, then climbed by 15.76% to $461.7 million in 2023, then climbed by 21.14% to $559.3 million in 2024.